Antoine G. van der Heijden
Radboud University Nijmegen
CancerInternal medicineUrologySurgeryPathologyOncologyProspective cohort studyCystectomyChemotherapyCarcinoma in situCystoscopyMitomycin CConcomitantMEDLINEHyperthermiaUrineContext (language use)Bladder cancerPerioperativeCancer researchNephrologyMedicineUrinary system
58Publications
22H-index
2,756Citations
Publications 60
Newest
#1Richard CathomasH-Index: 29
#2Anja Lorch (UZH: University of Zurich)H-Index: 21
Last. Matthew I. Milowsky (UNC: University of North Carolina at Chapel Hill)H-Index: 57
view all 18 authors...
Abstract null null Context null Treatment of metastatic urothelial carcinoma is currently undergoing a rapid evolution. null null null Objective null This overview presents the updated European Association of Urology (EAU) guidelines for metastatic urothelial carcinoma. null null null Evidence acquisition null A comprehensive scoping exercise covering the topic of metastatic urothelial carcinoma is performed annually by the Guidelines Panel. Databases covered by the search included Medline, EMBA...
Source
#1Anke Richters (Radboud University Nijmegen)H-Index: 6
#2Joost L. Boormans (EUR: Erasmus University Rotterdam)H-Index: 22
Last. Katja K.H. Aben (Radboud University Nijmegen)H-Index: 61
view all 8 authors...
BACKGROUND Cisplatin is preferred to carboplatin when treating metastatic urothelial carcinoma of the bladder (mUCB), despite its greater toxicity. Randomised studies underpinning this have been performed in noncontemporary populations with limitations in sample sizes and analyses, affecting their validity in current clinical practice. OBJECTIVE To estimate overall survival (OS) and assess the benefit of cisplatin-based regimens over carboplatin-based regimens in a contemporary cohort of patient...
Source
#1Guus W.B. Janssen (Cleveland Clinic)
#2Rathika R Ramkumar (Cleveland Clinic)H-Index: 2
view all 4 authors...
PURPOSE OF REVIEW Orthotopic urinary diversion (OUD), or neobladder, is believed to be the gold standard for surgical bladder reconstruction following radical cystectomy though it is performed far less often than ileal conduits. As both a continent and intracavitary diversion, OUDs offer unique advantages for patients. Their utilization has decreased overall though, especially with the advent of robotic surgery. In this review, we will cover patient selection for OUD, functional outcomes (i.e., ...
Source
#1Anke RichtersH-Index: 6
#2Richard P. Meijer (UU: Utrecht University)H-Index: 18
Last. Katja K.H. AbenH-Index: 61
view all 8 authors...
Introduction A better understanding of the molecular profile of bladder tumours, the identification of novel therapeutic targets, and introduction of new drugs and has renewed research interest in the field of bladder cancer. We describe the design and setup of a Dutch Prospective Bladder Cancer Infrastructure (ProBCI) as a means to stimulate and accelerate clinically meaningful experimental and observational research. Methods and analysis ProBCI entails an open cohort of patients with bladder c...
Source
#1Bas W.G. van RhijnH-Index: 54
#2Anouk E. Hentschel (VU: VU University Amsterdam)H-Index: 5
Last. Shahrokh F. Shariat (Charles University in Prague)H-Index: 136
view all 61 authors...
Abstract Background In the current European Association of Urology (EAU) non–muscle-invasive bladder cancer (NMIBC) guideline, two classification systems for grade are advocated: WHO1973 and WHO2004/2016. Objective To compare the prognostic value of these WHO systems. Design, setting, and participants Individual patient data for 5145 primary Ta/T1 NMIBC patients from 17 centers were collected between 1990 and 2019. The median follow-up was 3.9 yr. Outcome measurements and statistical analysis Un...
Source
#1R. Sylvester (European Association of Urology)H-Index: 18
#2Oscar Rodríguez (Autonomous University of Barcelona)H-Index: 9
Last. Jose Rubio-BrionesH-Index: 5
view all 61 authors...
Abstract Background The European Association of Urology (EAU) prognostic factor risk groups for non–muscle-invasive bladder cancer (NMIBC) are used to provide recommendations for patient treatment after transurethral resection of bladder tumor (TURBT). They do not, however, take into account the widely used World Health Organization (WHO) 2004/2016 grading classification and are based on patients treated in the 1980s. Objective To update EAU prognostic factor risk groups using the WHO 1973 and 2...
Source
#1Raquel Carrasco (University of Barcelona)H-Index: 1
#2Laura Izquierdo (University of Barcelona)H-Index: 15
Last. Antonio Alcaraz (University of Barcelona)H-Index: 44
view all 11 authors...
This study aimed to ascertain gene expression profile differences between progressive muscle-invasive bladder cancer (MIBC) and de novo MIBC, and to identify prognostic biomarkers to improve patients' treatment. Retrospective multicenter study in which 212 MIBC patients who underwent radical cystectomy between 2000 and 2019 were included. Gene expression profiles were determined in 26 samples using Illumina microarrays. The expression levels of 94 genes were studied by quantitative PCR in an ind...
Source
#1Thomas van Doeveren (EUR: Erasmus University Rotterdam)H-Index: 2
#2Jose A. Nakauma‐Gonzalez (EUR: Erasmus University Rotterdam)H-Index: 1
Last. Joost L. Boormans (EUR: Erasmus University Rotterdam)H-Index: 7
view all 17 authors...
The risk of developing urothelial carcinoma of the bladder (UCB) in patients treated by radical nephroureterectomy (RNU) for an upper urinary tract urothelial carcinoma (UTUC) is 22% to 47% in the 2 years after surgery. Subject of debate remains whether UTUC and the subsequent UCB are clonally related or represent separate origins. To investigate the clonal relationship between both entities, we performed targeted DNA sequencing of a panel of 41 genes on matched normal and tumor tissue of 15 pri...
Source
#1Iris S. G. Brummelhuis (Radboud University Nijmegen)H-Index: 5
#2Yvonne Wimper (Radboud University Nijmegen)H-Index: 1
Last. J. Alfred Witjes (Radboud University Nijmegen)H-Index: 89
view all 6 authors...
Background: The recurrence rate of non-muscle invasive bladder cancer (NMIBC) is high, despite intravesical treatments. Importantly, patients are frequently unfit or unwilling to undergo a recommended radical cystectomy when standard intravesical treatments fail, due to the substantial risk of morbidity and mortality. For these patients, radiofrequency-induced hyperthermia combined with intravesical chemotherapy (RF-CHT) has shown promising results. We aim to determine treatment outcomes and ass...
Source
Abstract Context This overview presents the updated European Association of Urology (EAU) guidelines for muscle-invasive and metastatic bladder cancer (MMIBC). Objective To provide practical evidence-based recommendations and consensus statements on the clinical management of MMIBC with a focus on diagnosis and treatment. Evidence acquisition A broad and comprehensive scoping exercise covering all areas of the MMIBC guideline has been performed annually since its 2017 publication (based on the 2...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.